

European network for pediatric research of the European Medicines Agency (Enpr-EMA)

Anne Junker, MD Director, MICYRN



- The EU situation: Enpr-EMA
- Trials in Canada
- MICYRN



Legislated January 2007

Improve the health of children:

- increase high quality ethical research into medicines for children
- increase availability of authorized medicines for children
- increase information on medicines

Achieve the above:

- without unnecessary studies in children
- without delaying authorization for adults Requirement to:
- develop a European network to coordinate studies



- To link together 64 existing networks
- To liaise with Industry and other stakeholders
- To define consistent and transparent quality standards
- To harmonize clinical trial procedures
- To define strategies for resolving major challenges
- To facilitate recruitment because this is a problem
- To strengthen research in Europe on European children



- To be as diverse as possible (therapeutic areas; ages; activities; trials/network organizations)
- Self-assessment process to qualify (# trials; ethics; GCP...)
- Wanted to include a total of 20 networks; only 16/32 met minimum criteria
- National networks: UK, Scottish, Finnish, Netherlands, Itl, MICYRN
- Specialty networks: CA-BMBT (4), PRINTO, E<u>CF</u>S, GNN, UKPVG, PENTA, but no Cardio, Critical Care/Pain,




- To provide secretarial support
- To organize and host meetings of the network
- To coordinate exchange of information between network partners
- To coordinate exchange of and provide information to external partners and stakeholders



- Launch meeting held March, 2011 (London, UK)
- Nomination of Chair of CG: Peter Helms (Scottish National Network)
- Main Goal established: Communication between Industry, Regulators, Patient Organizations
- 1st Action point: webpage, resource database
- Agreement to determine 3 main topics to develop model Paediatric Investigation Plans (PIPs)

maternal infant child & youth research network

Paediatric Committee (PDCO) Opinions on PIP Applications 2008-2010






Outcome after PDCO Review:

82% Deferrals to avoid delay in marketing

authorization for adults




Deferral : 82% of Paediatric Trials until after adult development

- 91% for new products
- 64% for existing products
- deferral of 4-5 years, up to 8y from MAA in adults


Olski TM et al Three years of the Pediatric Regulation in Europe Eur J Clin Pharmacol 2011 (in press)



Remains 9-10% relative to adult trials








* sites involved in pivotal clinical trials submitted for marketing authorization approval to the EMA per region per year




- World leader in pediatric pharmacology and development of trials methodology with contribution to international regulatory framework
- Biotech industry #2 in world (14.7B) and 80% of R&D directed to health products
- a Canadian child receives 4 prescriptions a year from a range of more than 1200 different drugs
- 75% of these drugs do not have dosing or safety data for use in children (90% for prematures)
- No legislation or incentives for Pediatric trials






Population 0-14 years: 16%




http://www.who.int/ictrp/en/

Health Conditions studied by child & youth research network more than 15 Pediatric Trials

maternal infant




Mon-Industry organizations are Primary Sponsor for 64% of Registered Pediatric Trials





Academic Institutions are sponsors for 94% of non-Industry Registered Pediatric Trials






- Only 12% of non-industry trials included sites outside Canada
- Only 14% of industry trials limited to Canada
- > 96 different companies conducted 314 trials (2005-2009)
- ➤ 54% of trials by 12 companies
- > 51 companies did only 1 study




Disorder	Company	Enrollment Target	Number of Countries listed for recruitment
Hemophilia	Bayer	139	25
Arthritis	Novartis	122	21
Influenza treatment	Hoffman LaRoche	250	19
Kidney disease	Sanofi Aventis	25	11
Asthma	Glaxo Smith Kline	300	11
Epilepsy	UCB Inc	357	11

✤ 25% of Industry trials listed an average of 12 countries to enroll \leq 500 study subjects.









- > 2nd to USA in total number of trials
- 3rd after Australia and Netherlands in number of trials/M births (maternal) or children (paediatric)
- Province-based academic organizations responsible for 94% of Canadian-sponsored trials



- Now incorporated as federal nonprofit society
- Joins the 17 child maternal research organizations in Canada
- Principal agenda to support multi-center collaborations
- Member interest in developing a national framework for multi-centre studies



- What works and what doesn't in doing Trials in Canada?
 - Methodologies, Ethics, New Frontiers
- How should we be engaging with patients, families and patient organizations?
- How should we be engaging with Industry?
- What do academic organizations require (reduce vulnerability) to support investigator-initiated studies? (DM, monitoring..)
- What can the academic organizations do to support networks?
- Determine how to qualify for CIHR-SPOR support as a (virtual) Support Unit or as a network of Support Units